STF-31

Description	in vitro: STF 31 is a glucose uptake inhibitor in RCC (renal cell carcinoma) 4 cells. By limiting glucose uptake in cancer cells, the immense energy requirements for the cancer cell is not met and the cell does not have the resources to rapidly proliferate.STF-31, which selectively kills RCCs by specifically targeting glucose uptake through GLUT1 and exploiting the unique dependence of these cells on GLUT1 for survival. STF-31 decreases glycolysis by decreasing glucose transport and not by inhibiting a particular glycolytic step or enzyme. STE31 is a potent glucose transporter 1 (GLUT1). STF31 selectively kills RCCs by specifically targeting glucose uptake through GLUT1 and exploiting the unique dependence of these cells on GLUT1 for survival. Treatment with STF31 inhibits the growth of RCCs by binding GLUT1 directly and impeding glucose uptake in vivo without toxicity to normal tissue. STF-31 is toxic to hPSCs and efficient for selective elimination of hPSCs from mixed cultures.
Pathways	GPCR/G Protein Others Pathway
Targets	Glucose Transporter Autophagy

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.